In their article, D'Orazio and colleagues provided a comprehensive overview of the epidemiology, pharmacology, and clinical effects of exposure to xylazine in humans as an adulterant in opioids, along with recommendations and suggested research questions. The editorialists discuss the importance of comprehensive surveillance of xylazine use and poisonings.